Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.59 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.59 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256223 | 0.88 | EPHX2 (1.00) | EPHX2AURKAAURKB | |
| SCHEMBL4262990 | 0.84 | EPHX2 (1.00) | EPHX2AURKAAURKBGAANPC1 | |
| SCHEMBL4256144 | 0.82 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4264251 | 0.81 | EPHX2 (1.00) | EPHX2HRH3 | |
| SCHEMBL4266421 | 0.78 | EPHX2 (1.00) | EPHX2GAA | |
| SCHEMBL4262609 | 0.78 | EPHX2 (1.00) | EPHX2HRH3 | |
| SCHEMBL4257596 | 0.78 | EPHX2 (0.64) | EPHX2AURKAAURKB | |
| SCHEMBL13949472 | 0.78 | EPHX2 (0.64) | EPHX2AURKAAURKB | |
| SCHEMBL12932148 | 0.77 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4256229 | 0.77 | EPHX2 (0.64) | EPHX2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | claimed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008116145-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116145-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885AURKA 4806/4885AURKB 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.